15 More Medicare Drugs Are Getting Negotiated Prices in 2027. Is Yours on the List?

The Inflation Reduction Act gave Medicare the power to negotiate drug prices directly with manufacturers for the first time in the program's history. The first ten negotiated prices took effect January 1, 2026. Now CMS has announced the second round: fifteen more drugs with negotiated Maximum Fair Prices taking effect January 1, 2027.

If you take any of these fifteen medications and you have Medicare Part D, this news is directly relevant to what you will pay at the pharmacy starting next year. But understanding the difference between a lower negotiated price and a lower out-of-pocket cost for you specifically takes a little more unpacking.

Which 15 Drugs Are Being Negotiated

CMS announced the selection of these fifteen Part D drugs for the second cycle of negotiations in January 2025, and confirmed in March 2025 that all manufacturers had agreed to participate. CMS announced the Maximum Fair Prices for these drugs in November 2025, with the new prices taking effect January 1, 2027.

The fifteen drugs are: Austedo and Austedo XR (deutetrabenazine), Breo Ellipta (fluticasone/vilanterol), Calquence (acalabrutinib), Ibrance (palbociclib), Janumet and Janumet XR (sitagliptin/metformin), Linzess (linaclotide), Ofev (nintedanib), Otezla (apremilast), Ozempic, Rybelsus, and Wegovy (semaglutide), Pomalyst (pomalidomide), Tradjenta (linagliptin), Trelegy Ellipta (fluticasone/umeclidinium/vilanterol), Vraylar (cariprazine), Xifaxan (rifaximin), and Xtandi (enzalutamide).

Approximately 5.3 million people with Medicare Part D used these fifteen drugs between January 2024 and December 2024, accounting for $42.5 billion in total gross covered drug costs during that period.

How Much Are Prices Dropping

CMS reported an overall net savings of approximately 44 percent across the fifteen drugs, representing an estimated $12 billion in savings compared to Medicare's 2024 net spending on these medications.

The most widely discussed price reduction is for Ozempic, Rybelsus, and Wegovy. The negotiated Maximum Fair Price for these semaglutide products is $274 per month, representing a reduction of approximately 71 percent from their 2024 list prices.

Ellen can help you understand your coverage and build an appeal if needed. Start here →